Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study.

Expert Review of Anti-infective Therapy
Krzysztof TomasiewiczRobert Flisiak

Abstract

Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. Twenty-eight patients were included (19 male), with a mean age of 61.7 ± 12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 ± 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p < 0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p ≤ 0.001). Lung changes improved in 21 (84%) patients within two weeks of treatment; 19 had minimal or no changes upon final examination. Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in...Continue Reading

References

Jan 15, 2011·Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders·Graeme Jones, Changhai Ding
Dec 10, 2017·Scientific Reports·Jiajia ChenLanjuan Li
Mar 17, 2020·AJR. American Journal of Roentgenology·Sana SalehiAli Gholamrezanezhad
Mar 18, 2020·Clinica Chimica Acta; International Journal of Clinical Chemistry·Giuseppe LippiBrandon Michael Henry
Apr 4, 2020·BMJ : British Medical Journal·Michael Day
Apr 8, 2020·Journal of Medical Virology·Pan LuoJuan Li
May 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Xiaoling XuHaiming Wei
May 1, 2020·The Lancet. Respiratory Medicine·Ricardo J Jose, Ari Manuel
May 15, 2020·Journal of Thoracic Imaging·Sana SalehiAli Gholamrezanezhad
May 15, 2020·European Journal of Internal Medicine·Ruggero CapraStefania Cossi
May 22, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Giovanni FilocamoAlessandra Bandera
May 26, 2020·European Journal of Internal Medicine·Valentina MorenaMario Corbellino
Jun 3, 2020·European Journal of Internal Medicine·Corrado CampochiaroAlberto Zangrillo
Aug 25, 2020·The Lancet Rheumatology·Thomas HuetGilles Hayem

❮ Previous
Next ❯

Citations

Aug 29, 2020·European Journal of Medical Research·Regina B PodlasinAndrzej Horban
Dec 22, 2020·Expert Opinion on Pharmacotherapy·Iwona HusTadeusz Robak
Jan 22, 2021·BMJ : British Medical Journal·Viviane C VeigaUNKNOWN Coalition covid-19 Brazil VI Investigators
Oct 30, 2020·International Journal of Molecular Sciences·Jan BrábekKarel Smetana
Apr 8, 2021·Expert Review of Clinical Immunology·Soheila RezaeiReza Mosaed
Apr 25, 2021·Transplantation Proceedings·Karolina Kędzierska-KapuzaMarek Durlik
May 1, 2021·Journal of Clinical Medicine·Robert FlisiakDorota Zarębska-Michaluk
Dec 24, 2020·Expert Review of Anti-infective Therapy·Md Jamal Hossain, S M Abdur Rahman
Jun 3, 2021·International Journal of Molecular Sciences·Joanna KulikowskaAlina Kułakowska
Jun 25, 2021·Expert Opinion on Drug Safety·Jaykaran CharanMainul Haque
Jul 1, 2021·Oxford Open Immunology·Patrícia R S RodriguesLuke C Davies
Jul 24, 2021·Journal of Inflammation Research·Dorota Zarębska-MichalukRobert Flisiak

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
X-ray

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Archives of Medical Science : AMS
Nicola Lucio LiberatoGiuseppe Caravella
JAMA Internal Medicine
Lucy C K Bell, Gabriele Pollara
JAMA Internal Medicine
Chengliang Yang, Mingyao Liu
JAMA Internal Medicine
Jean-François RossiBernard Klein
© 2021 Meta ULC. All rights reserved